Sugi Predict

Sugi Predict / Targets / RAB29

RAB29

Ras-related protein Rab-7L1 · O14966 · RAB29 on Sugi Atlas →

327 patent compounds predicted against RAB29, 288 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1623566 SCHEMBL1623566 1.00 1/20
SCHEMBL1623635 SCHEMBL1623635 0.85 1/20
SCHEMBL1620935 SCHEMBL1620935 0.84 1/20
SCHEMBL1623685 SCHEMBL1623685 0.83 1/20
SCHEMBL1624415 SCHEMBL1624415 0.83 1/20
SCHEMBL1623944 SCHEMBL1623944 0.82 1/20
SCHEMBL1621534 SCHEMBL1621534 0.81 1/20
SCHEMBL1623689 SCHEMBL1623689 0.81 1/20
SCHEMBL4595843 SCHEMBL4595843 0.81 1/20
SCHEMBL1624093 SCHEMBL1624093 0.80 1/20
SCHEMBL4594995 SCHEMBL4594995 0.80 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1623815) 0.79 1/20
SCHEMBL1621497 SCHEMBL1621497 0.78 1/20
SCHEMBL1623711 SCHEMBL1623711 0.78 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1623887) 0.78 1/20
SCHEMBL1622913 SCHEMBL1622913 0.78 1/20
SCHEMBL1624190 SCHEMBL1624190 0.78 1/20
SCHEMBL1623277 SCHEMBL1623277 0.77 1/20
SCHEMBL1623763 SCHEMBL1623763 0.76 1/20
SCHEMBL12754224 SCHEMBL12754224 0.75 1/20

Clinical trials — most relevant to RAB29 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47) PHASE1/PHASE2NOT_YET_RECRUITING
Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK PHASE1/PHASE2RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer PHASE1/PHASE2COMPLETED
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation PHASE2COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Identification of New Biomarkers of Insulin Resistance nanACTIVE_NOT_RECRUITING
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Fox BioNet Project: LRRK2-002 nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Study of Chediak-Higashi Syndrome nanRECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients nanCOMPLETED
Parkinson's Families Project nanRECRUITING
Pubertal Development in Patients with RASopathies nanRECRUITING
Genetic Studies of Chronic Active Epstein-Barr Disease nanRECRUITING
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
Investigating Phenotypic, Epigenetic, and NeuroGenetic Traits in Rare and Ultra-rare Neurodevelopmental Disorders (Project PENGUIN) nanRECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Gene Analysis of Parkinson's Disease nanCOMPLETED
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RAB29 binder may also engage these)

ProteinNameSimilarity
Q5R7A4 — 1.000 Q5R7A4 →
Q91YQ1 — 1.000 Q91YQ1 →
Q63481 — 1.000 Q63481 →
RAB9A Ras-related protein Rab-9A 0.994 landscape →
P93267 — 0.993 P93267 →
Q8BHD0 — 0.992 Q8BHD0 →
Q9C820 — 0.991 Q9C820 →
RAB39A Ras-related protein Rab-39A 0.991 landscape →
Q43463 — 0.990 Q43463 →
P31022 — 0.990 P31022 →
C8VQY7 — 0.990 C8VQY7 →
Q9SJ11 — 0.989 Q9SJ11 →
P24408 — 0.989 P24408 →
P46629 — 0.989 P46629 →
P09527 — 0.989 P09527 →
Q9H082 — 0.989 Q9H082 →
Q3T0F5 — 0.989 Q3T0F5 →
Q9SIP0 — 0.989 Q9SIP0 →
Q9R0M6 — 0.989 Q9R0M6 →
Q5R4W9 — 0.989 Q5R4W9 →
P19892 — 0.989 P19892 →
Q5R615 — 0.989 Q5R615 →
Q99P75 — 0.988 Q99P75 →
Q9XI98 — 0.988 Q9XI98 →
Q9HDY0 — 0.988 Q9HDY0 →
Q9C2L8 — 0.988 Q9C2L8 →
P91580 — 0.988 P91580 →
Q9LS94 — 0.988 Q9LS94 →
O97572 — 0.988 O97572 →
Q9CZE3 — 0.988 Q9CZE3 →